ArticleMikrochimica acta2026
Label-free baseline-calibrated electrochemical immunosensor for carcinoembryonic antigen detection using electro-synthesized silver nanoparticles and citrate-capped NiFe₂O₄ nanoparticles on a glassy carbon electrode.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early cancer diagnosis is vital for improving patient survival. The present work uses a novel and label-free baseline calibrated electrochemical immunosensor for the sensitive detection of carcinoembryonic antigen (CEA). The sensor platform was constructed on a glassy carbon electrode (GCE) modified with electro-synthesized silver nanoparticles (e-AgNPs) and carboxyl-functionalized NiFe₂O₄ nanoparticles (cit-NFO-COOH). This nanocomposite enhanced the electrode surface area, conductivity, and antibody immobilization stability. Comprehensive material characterization was performed using Fourier transform infrared spectroscopy (FTIR), field emission scanning electron microscopy (FESEM), energy dispersive X-ray (EDX), X-Ray diffraction analysis (XRD), and dynamic light scattering (DLS), and zeta potential analysis, while electrochemical performance was evaluated via cyclic and differential pulse voltammetry. Optimization studies disclosed that the optimal concentrations for AgNO₃, cit-NFO-COOH, and antibody were 0.05 mM, 1000 mg/L, and 20 µg/mL, respectively. The fabricated immunosensor exhibited a wide linear detection range (0.1 pg/mL to 10 ng/mL) with a linear regression equation of y = 0.2306ln [CEA] + 3.0227 (R² = 0.999) and an exceptionally low detection limit of 0.09 pg/mL. The precision and accuracy of the probe for intraday and interday tests were assessed as mean relative standard deviation (RSD%) and relative error (RE%) with values of 4.1%, 3.0%, 10.2%, and 10.9%, respectively. Also, specificity was tested in the presence of various biologically available biomarkers and biomolecules with absolute mean change of 8.2%. The validation results were confirmed following the Food and Drug Administration (FDA) guidelines for developing sensing platforms in biological media. The high sensitivity and stability of this biosensor highlight its significant potential as a powerful tool for clinical application in cancer biomarker monitoring.
Indexed as
Identifiers
41642411What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.